Phase 1 Clinical Trial Results

Phase 2 Clinical Trial Results

OncoGenex’ Phase 3 compound, custirsen, is designed to inhibit the production of clusterin, an antiapoptotic, stress-induced protein that confers treatment resistance when overexpressed in a variety of tumors. Custirsen has completed five Phase 2 clinical trials in prostate, lung and breast cancers. Data from these Phase 2 studies demonstrates the potential benefit of adding custirsen, a second-generation antisense molecule, to existing cancer therapies.

OncoGenex is collaborating with Teva Pharmaceuticals on a global clinical development program. Two Phase 3 studies in castrate-resistant prostate cancer are currently enrolling patients throughout North America and Europe. A Phase 3 study in patients with non-small cell lung cancer is planned to initiate in 2012.

SYNERGY: A randomized, controlled, international trial to evaluate a survival benefit for custirsen in combination with first-line docetaxel treatment in approximately 1000 patients with CRPC.

For more information about the SYNERGY trial click here

SATURN: A randomized, controlled, international trial to evaluate a durable pain palliation benefit for custirsen in combination with second-line chemotherapy in approximately 300 patients with CRPC .

For more information about the SATURN trial click here